Beatriz Ruz-Caracuel

Ms. Beatriz Ruz-Caracuel

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2021 in Pediatric Hematology and Oncology
Verified
Journal Article
Closed access
YMYasmina Mozo
Yasmina Mozo
DBDavid Bueno
David Bueno
LSLuisa Sisinni
Luisa Sisinni
AFAlba Fernández-Arroyo
Alba Fernández-Arroyo
BRBlanca Rosich
Blanca Rosich
BRBeatriz Ruz-Caracuel
Beatriz Ruz-Caracuel
Ruxolitinib, a selective Janus Kinase (JAK) 1/2 inhibitor, is a promising treatment for the steroid-refractory graft-vs-host disease (GvHD) after hematopoietic stem cell transplantation (HSCT). Most studies have been performed in the adult population showing efficacy against GvHD. In this retrospective study, we evaluated the outcomes of 19 children who received ruxolitinib for refractory acute or chronic GvHD (cGvHD) after HSCT from two Pediatric Hemato-Oncology Departments in Spain between March 2017 and December 2018. Patients received a median number of 4 (IQR 2) previous lines of treatment before starting ruxolitinib. The overall response rate in acute GvHD (aGvHD) and cGvHD was 87% and 91%, respectively. Complete response (CR) was observed in 37% of aGvHD and 8.3% of cGvHD. Remarkably, 43% and 40% of patients with steroid-refractory gastrointestinal aGvHD and lung cGvHD achieved CR. During ruxolitinib treatment, there were 36%, 31%, and 10% infections caused by viruses, bacteria, and fungi, respectively. Overall, four patients interrupted ruxolitinib due to infectious complications, hematological, and liver toxicity. The 2-year overall survival was 71.9% (CI 95% 58.6–85.2). Our experience supports the use of ruxolitinib as an effective treatment for steroid-refractory acute and cGvHD in children with a moderate toxicity profile.

1 May 2021 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
LGLara Maria Gómez García
Lara Maria Gómez García
AEAdela Escudero
Adela Escudero
CMCarmen Mestre
Carmen Mestre
JSJose L Fuster Soler
Jose L Fuster Soler
AMAntonia Pascual Martínez
Antonia Pascual Martínez
Antonio Pérez MartínezAntonio Pérez Martínez
Antonio Pérez Martínez

9 February 2024 in European Journal of Haematology
Verified
Journal Article
Closed access
CECarlos Echecopar
Carlos Echecopar
IAInés Abad
Inés Abad
VGVíctor Galán‐Gómez
Víctor Galán‐Gómez
YCYasmina Mozo del Castillo
Yasmina Mozo del Castillo
LSLuisa Sisinni
Luisa Sisinni
Antonio Pérez MartínezAntonio Pérez Martínez
Antonio Pérez Martínez

Verified
Journal Article
Open access
PDF file
VGVíctor Galán-Gómez
Víctor Galán-Gómez
NMNerea Matamala
Nerea Matamala
BRBeatriz Ruz-Caracuel
Beatriz Ruz-Caracuel
PVPaula Valle-Simón
Paula Valle-Simón
BOBárbara Ochoa-Fernández
Bárbara Ochoa-Fernández
AEAdela Escudero
Adela Escudero
Relapsed and refractory (R/r) disease in paediatric acute leukaemia remains the first reason for treatment failure. Advances in molecular characterisation can ameliorate the identification of genetic biomarkers treatment strategies for this disease, especially in high-risk patients. The purpose of this study was to analyse a cohort of R/r children diagnosed with acute lymphoblastic (ALL) or myeloid (AML) leukaemia in order to offer them a targeted treatment if available. Advanced molecular characterisation of 26 patients diagnosed with R/r disease was performed using NGS, MLPA, and RT-qPCR. The clinical relevance of the identified alterations was discussed in a multidisciplinary molecular tumour board (MTB). A total of 18 (69.2%) patients were diagnosed with B-ALL, 4 (15.4%) with T-ALL, 3 (11.5%) with AML and 1 patient (3.8%) with a mixed-phenotype acute leukaemia (MPL). Most of the patients had relapsed disease (88%) at the time of sample collection. A total of 17 patients (65.4%) were found to be carriers of a druggable molecular alteration, 8 of whom (47%) received targeted therapy, 7 (87.5%) of them in addition to hematopoietic stem cell transplantation (HSCT). Treatment response and disease control were achieved in 4 patients (50%). In conclusion, advanced molecular characterisation and MTB can improve treatment and outcome in paediatric R/r acute leukaemias.

16 August 2023 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
VGVictor Galán
Victor Galán
CBCristina Belendez
Cristina Belendez
CECarlos Echecopar
Carlos Echecopar
PEPablo Estival
Pablo Estival
LSLuisa Sisinni
Luisa Sisinni
APAntonio Pérez-Martínez
Antonio Pérez-Martínez
Data on treosulfan-based conditioning regimens are little by little increasing, and the benefits of this approach are consistent, particularly regarding acute toxicity. This study aims to describe the results of treosulfan-based conditioning regimens in children, focusing on toxicity and outcomes when used to treat both malignant and non-malignant diseases. Retrospective observational study on pediatric patients treated in Spain with treosulfan-based conditioning regimens before hematopoietic stem cell transplantation (HSCT), based on data collection from electronic clinical records. One hundred and sixty treosulfan-based conditioning HSCTs to treat non-malignant diseases (n=117) or malignant diseases (n=43) in 158 children and adolescents are reported. Median age at HSCT was 5.1 years (IQR: 2-10). The most frequent diagnoses were primary immunodeficiency (n=42; 36%) and sickle cell disease (n=42; 36%) in the non-malignant cohort and acute lymphoblastic leukemia (n=15; 35%) in the malignant cohort. Engraftment occurred in 97% of the patients. There was a longer median time to neutrophil engraftment (17 vs. 14 days; p=0.008) and platelet engraftment (20 vs. 15 days; p=0.002) in the non-malignant cohort. The 1-year cumulative incidence of VOD was 7.98 (95%CI [4.6-13.6]), with no significant differences between cohorts. The 1-year cumulative incidence of grade III-IV aGvHD was higher in the malignant cohort (18% vs. 3.2%; p=0.011). Overall, cGvHD was more frequently observed in the malignant cohort for both total incidence (9 vs. 3%; p<0.001) and 2-year cumulative incidence of total cGvHD (16 vs. 1.9%; p<0.001). The 2-year cumulative TRM was 15%, with no differences between cohorts. 5-year Overall Survival was 80% (95%CI [72-86]) and was higher in the non-malignant cohort (87 vs. 61%; p=0.01). The 2-year cumulative incidence of relapse in the malignant cohort was 25%. 5-year cumulative GRFS rate was 60% (95%CI [51-70]) and was higher in the non-malignant cohort (72 vs. 22%; p<0.001). The treosulfan-based radiation-free conditioning regimen is feasible, achieving a high engraftment rate and 5-year overall survival. A treosulfan-based conditioning regimen is an emerging option for the first HSCT in non-malignant diseases.